Core Viewpoint - The company reported a revenue growth of 5.26% to 1.915 billion yuan and a net profit increase of 82.65% to 163 million yuan for the year 2024 [1] Group 1: Financial Performance - Revenue increased by 5.26% to 1.915 billion yuan [1] - Net profit rose by 82.65% to 163 million yuan [1] Group 2: Store Expansion and Business Development - The number of retail stores reached 206, with a net increase of 35 stores, including 2 new pet specialty stores [4] - The company opened its first pet-friendly pharmacy in June 2024, recognized by the Shanghai Commercial Industry Association [4] - The company added 53 new medical insurance stores, with over 60% of stores covered by medical insurance, exceeding the average coverage in Shanghai [4] - A total of 24 new franchise stores were added, with franchise sales exceeding 50 million yuan for the year [4] Group 3: New Business Initiatives - The company ranked among the top 4 in O2O sales in Shanghai, showing significant improvement [4] - Cross-border sales of health products were initiated through its subsidiary, enhancing the product line and obtaining qualifications for cross-border drug sales [4] Group 4: Strategic Partnerships and Services - The company transferred 49% of its wholly-owned subsidiary, Deep Sea Medicine, to develop SPD business for wholesale growth [5] - A traditional Chinese medicine decoction service center was established, aiming to provide more personalized services [5] Group 5: Digital Transformation - The company’s membership mini-program recorded over 43,000 new registrations in 2024 [6] - A modern intelligent logistics center is under construction, expected to enhance logistics efficiency and reduce costs by 2025 [6]

Core Insights - The company reported a total revenue of 1.915 billion yuan for 2024, representing a year-on-year growth of 5.26%, while the net profit attributable to shareholders reached 163 million yuan, up 82.65%. However, the non-recurring net profit plummeted by 36.79% to only 6.874 million yuan, indicating deeper issues in its business transformation despite progress in retail expansion, online business, and cross-border sales [1] Retail Expansion - In 2024, the company achieved significant progress in retail expansion, adding 35 new stores, bringing the total to 206. This included 2 new pet specialty stores and 53 medical insurance stores, with the latter accounting for over 60% of the total, surpassing the average level in the Shanghai market. Additionally, the company expanded through a franchise model, adding 24 franchise stores with sales exceeding 50 million yuan. However, the increase in store numbers did not translate into improved profitability, as indicated by the sharp decline in non-recurring net profit, highlighting high operational costs and insufficient profitability, particularly in innovative store formats like pet specialty stores and health towns [4] Online Business and Cross-Border Sales - The company's online business continued to grow in 2024, ranking among the top four in O2O sales in Shanghai, showing significant improvement compared to previous years. The company leveraged partnerships with platforms and utilized marketing resources to achieve a surge in traffic and sales. Furthermore, the company expanded its cross-border sales through its subsidiary, acquiring qualifications for cross-border drug purchases. Despite the notable growth in online and cross-border sales, their contribution to overall profits remains limited, as online sales have low profit margins and cross-border sales are still small-scale, posing compliance risks and increasing operational costs [5] Backend Support and Digitalization - In 2024, the company made substantial investments in backend support and digitalization, optimizing procurement costs, introducing JBP suppliers, and developing OEM products to enhance supply chain efficiency. The company also launched a chronic disease management service system, registering over 43,000 individuals, and initiated a modern intelligent logistics center project expected to be completed by 2025. However, the effectiveness of these investments is yet to be seen, as the improvements in operational efficiency have been limited. The long construction cycle of the logistics center may delay significant benefits, and while investments in talent acquisition and training have strengthened the internal workforce, their impact on business growth requires further validation [6]

Meeting Overview - The meeting took place in March 2025, with both onsite and online participation [1] - Attendees included representatives from various securities firms and investment funds [1] Cost Reduction and Efficiency Improvement - The company established a special task force for cost reduction and efficiency improvement, focusing on organizational reform and process reengineering [1] - Specific measures include enhancing management efficiency through talent development, standardizing procurement processes, optimizing property resources, and strengthening financial controls [1] Chronic Disease Management Services - The company offers comprehensive health management services for chronic disease patients, utilizing digital tools to enhance service quality and customer retention [2] - As of Q3 2024, the company has established health records for over 16.84 million chronic disease patients, with a higher repurchase rate for chronic disease self-test members compared to regular members [2] - The company has equipped 9,352 stores with free self-testing devices for chronic diseases [2] Franchise Business Strategy - The franchise business is a key strategic focus for the company, leveraging its asset-light model to rapidly expand market presence [3] - The franchise model allows better penetration into county and town markets, benefiting from local franchisees' customer loyalty and resource advantages [3] - The company has a strong brand influence and operational management capabilities, with over 20 years in the pharmaceutical retail industry [3]